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Natural killer (NK) cells are part of the innate immune response and play a crucial role in
the defense against tumors and virus-infected cells. Their effector functions include the
specific killing of target cells, as well as the modulation of other immune cells by cytokine
release. Kinases constitute a relevant part in signaling, are prime targets in drug research
and the protein kinase inhibitor Dasatinib is already used for immune-modulatory therapies.
In this study, we tested the effects of the kinase inhibitors CK59 and CID755673. These
inhibitors are directed against calmodulin kinase II (CaMKII; CK59) and PKD family kinases
(CID755673) that were previously suggested as novel components of NK activation path-
ways. Here, we use a multi-parameter, FACS-based assay to validate the influence of CK59
and CID755673 on the effector functions of primary NK cells. Treatment with CK59 and
CID755673 indeed resulted in a significant dose-dependent reduction of NK cell degranu-
lation markers and cytokine release in freshly isolated Peripheral blood mononuclear cell
populations from healthy blood donors. These results underline the importance of CaMKII
for NK cell signaling and suggest protein kinase D2 as a novel signaling component in
NK cell activation. Notably, kinase inhibition studies on pure NK cell populations indicate
significant donor variations.
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INTRODUCTION
Natural killer (NK) cells establish the first line of innate immune
defense against pathogen-infected cells and tumor cells, as well as
a certain set of hematopoietic cells (Vivier et al., 2008; Bryceson
et al., 2009), a process also known as natural cytotoxicity.
Natural cytotoxicity encompasses coordination of following
steps: contact with target cells, adhesion, synapse formation, gran-
ule polarization, and granule exocytosis. These steps are mainly
under the control of a multiplicity of germline-encoded activat-
ing and inhibitory surface receptors, which bind ligands expressed
on target cells (Bryceson et al., 2006, 2011; Lanier, 2008; Pegram
et al., 2010). In addition to natural cytotoxicity, NK cells medi-
ate antibody-dependent cellular cytotoxicity (ADCC). ADCC
depends on FcγRIIIA receptor expression (CD16), so that cells can
become targets that do normally not activate NK effector responses
(Forthal et al., 1999). In contrast, natural cytotoxicity occurs inde-
pendently of antigen recognition and is mainly studied in vitro by
using cell lines like K562 (Hanson et al., 2007).
K562 target cells express very low amounts of MHC class I
(missing self). However, natural cytotoxicity depends not only on
an absent inhibitory signal, but also on activating signals that are
necessary for NK activation and tumor cell lysis (Moretta et al.,
2000). Hence, K562 cells express ligands that bind activating NK
cell receptors, e.g., ULBP2 and MICA/B, the ligands of NKG2D (Li
et al., 2008), B7–H6 as the ligand of NKp30 (Brandt et al., 2009)
and Nectin-2, which acts as a ligand for DNAM-1 (Moretta et al.,
2000). K562 do not express CD48 (the 2B4 NK receptor ligand),
as well as classical (HLA-A, B, C) and non-classical (HLA-E) HLA
class I molecules (Hanson et al., 2007). Additionally, natural cyto-
toxicity leads to the secretion of pro-inflammatory cytokines like
TNF-α and IFN-γ (Vivier et al., 2008) and can be further triggered
by supplementing interleukins like IL-2, IL-12, IL-18, as well as
IFN-γ.
After receptor engagement, protein kinases, like Protein Kinase
C-θ (PKCθ), Phophatidyl-inositol-3-OH kinase (PI3K) or Src
family kinases (SFKs) like FYN, induce signaling networks con-
trolling NK cell effector functions (Brumbaugh et al., 1997; Kerr
and Colucci, 2011; Merino et al., 2012). ADCC- and natural
cytotoxicity-induced signal transduction pathways share many sig-
naling components and a kind of core signaling network was
suggested (König et al., 2012). The same study described post-
translational responses of kinases following NK cell activation
indicating their role in proximal signaling pathways. Among 188
kinases that were characterized by accurate mass spectrometry
in IL-2-expanded human NK cells, an increased phosphoryla-
tion of FYN, the Calcium/Calmodulin Kinase II (CaMKII) and
Protein Kinase D2 (PKD2), was reproducibly observed after recep-
tor engagement (König et al., 2012). Nevertheless, our knowledge
about the signaling controlling ADCC/natural cytotoxicity is very
fragmentary to this date.
Modulation of immune responses is a general therapeutic strat-
egy. Up to now, NK cell based therapies against cancer are per-
formed by using IL-2 or other antibody-based therapies (Vivier
et al., 2012). Furthermore, clinically relevant kinase inhibitors
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were recognized to cause significant immune-modulatory effects.
Studies on NK cells were conducted by using kinase inhibitors,
like Imatinib and Nilotinib, both specifically targeting BCR/ABL,
PDGFR, and c-KIT, as well as on Dasatinib, which is additionally
directed against the Src kinase family. These studies confirmed
their direct inhibitory effects on NK cell effector functions (Krieg
and Ullrich, 2012).
In the case of Dasatinib, a direct inhibition of NK cell effec-
tor functions resulted from its effects on PI-3 kinase and ERK1/2
signaling cascades (Salih et al., 2010).
The protein kinase CaMKII was previously described to play
an important role in NK cell activation, after being induced by
lymphocytes function-associated antigen 1 (LFA-1). Adding the
CaMKII inhibitors KN62/KN93 reduced the secretion of lytic
granules and the cytotoxic activity remarkably in CD3−CD16+
NK cells. Furthermore, it was shown that the HIV-1 Tat protein is
able to block calcium influx and impairs CaMKII induction, which
points to a clinical relevance of the CaMKII kinase (Poggi et al.,
2002).
The PKD kinase family has been implicated in a variety of
cellular processes, including cell proliferation, cell survival (Storz
et al., 2003), gene expression (Ha et al., 2008), protein traffick-
ing (Bankaitis, 2002), cell motility (Prigozhina and Waterman-
Storer, 2004), and immune responses (Matthews et al., 2012). PKD
kinases are frequently de-regulated in cancer, become of interest in
tumor biology and are considered as therapeutic targets for drug
development and applications in immunotherapy (Chen et al.,
2008).
In this study and beside of Dasatinib, the next generation
CaMKII inhibitor CK59, which specifically binds CaMKII-β and
CaMKII-δ (Konstantopoulos et al., 2007) and the PKD family
directed kinase inhibitor CID755673 (Sharlow et al., 2008; George
et al., 2011) were used to determine their potential effects on
NK cell effector functions. Peripheral blood mononuclear cells
(PBMCs), isolated from human blood donations, were pre-treated
with various doses of these drugs and degranulation, TNF-α and
IFN-γ secretion were analyzed by multicolor FACS measurements.
In addition to the results of Salih et al. (2010), we observed
remarkably reduced TNF-α release and degranulation events after
Dasatinib treatment. Application of the further improved CK59
(CaMKII-directed) inhibitor led to strongly abrogated NK cell
degranulation and cytokine release, but an even more pronounced
reduction of NK cell effector functions was observed after using
CID755673. Additionally, this study revealed significant donor
variations at the level of primary NK cells.
MATERIALS AND METHODS
HUMAN SUBJECTS AND CELL LINES
Buffy coats from the blood of healthy human volunteers were
obtained from the Institute for Clinical Transfusion Medicine,
Klinikum Braunschweig, Germany. Leukocyte-depleted periph-
eral blood from regular donations was anonymized in accordance
with the guidelines of the Declaration of Helsinki. PBMCs were
isolated from buffy coats by Biocoll density gradient centrifugation
(Biochrome AG). PBMCs were directly used for experiments or
cultured in complete RPMI 1640 medium (GIBCO) supplemented
with 10% fetal bovine serum (FBS) gold (PAA Laboratories),2 mM
l-glutamine, 50 units/ml penicillin and 50µg/ml streptomycin (all
Invitrogen). The human erythroleukemia cell line K562 (kindly
provided by Dr. P. Riese – Department of Vaccinology; Helmholtz
Centre for Infection Research, Braunschweig) was maintained in
RPMI 1640 (Gibco) supplemented with 10% FBS gold (PAA Lab-
oratories), 50 units/ml penicillin, and 50µg/ml streptomycin (all
Invitrogen). NK cells were isolated from PBMCs using the NK
cell isolation kit (Miltenyi) according to the manual. Isolated
NK cells were incubated in IMDM (Gibco), supplemented with
10% human serum, 2 mM l-glutamine, 50 units/ml penicillin and
50µg/ml streptomycin, 1% Sodium Pyruvate, and 1% NEAA (all
Invitrogen).
ANTIBODIES AND FLUORESCENT REAGENTS
The following fluorochrome-conjugated monoclonal antibodies
(mAbs) were used for flow cytometry: anti-CD3 (BW264/56, Mil-
tenyi), anti-CD56 (AF12-7H3, Miltenyi), anti-CD107a (H4A3;
BioLegend); anti-CD14 (MΦP9, BD Bioscience), anti-CD19
(SJ25C1, BD Bioscience), anti-TNF-α (MAb11; eBioscience), and
anti-IFN-γ (25723, BD Bioscience). A fixable cell viability cell dye
(LIVE/DEAD near IR Cell Stain; 405 nm Invitrogen) was used to
exclude dead cells from the analysis.
DEGRANULATION AND CYTOKINE RELEASE ASSAY
Degranulation events and cytokine release were assessed as
described previously (Bryceson et al., 2010). In brief, resting
PBMCs or pure NK cells were incubated for 15 min at 37˚C,
7.5% CO2 with the indicated dilutions of the kinase inhibitors
(CK59-Merck; CID755673-TOCRIS BIOSCIENCE; Dasatinib-LC
Laboratories) in complete RPMI 1640 medium. Cells were mixed
with their natural target cells, K562 in V-bottomed 96-well plates
at a ratio of 10:1 for assessing TNF-α and IFN-γ release and in
a ratio of 1:1 for NK cell degranulation assays. IL-12 (10 ng/ml)
and IL-18 (100 ng/ml; both from PeproTech) were added to deter-
mine cell viability and responsiveness as indicated (Figure A2
in Appendix). Cells were centrifuged at 30× g for 3 min and
incubated for 1 h at 37˚C and 7.5% CO2. Thereafter, GolgiPlug
and GolgiStop (both BD Bioscience) were added and cells were
incubated for further 2 h to assess NK cell degranulation and for
another 5 h to analyze cytokine release. Effector cells treated with
DMSO served as negative controls. After incubation, cells were
harvested by centrifugation (450× g, 3 min) and surface stained
(CD3, CD56, CD107a, CD14, CD19). After fixation (2% PFA) and
permeabilization (0.5% Saponin in PBS) cells were intracellularly
stained with fluorochrome-conjugated mAbs against IFN-γ and
TNF-α.
FLOW CYTOMETRIC ANALYSIS
Analysis of degranulation and cytokine release was carried out on
a BD LSR II Flow Cytometer (BD Biosciences), using the FACS-
Diva (BD Biosciences) software for compensation. Data analysis
was performed by using FlowJo version 7.6.5 (Treestar).
STATISTICAL ANALYSIS
In each experiment we used at least five human blood donors,
from which two technical replicates were generated that defined
groups for further statistical analyses. Comparison of inhibitor-
treated groups to their corresponding DMSO control group was
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performed by Wilcoxon test (*P < 0.05, **P < 0.01, ***P < 0.001).
Statistical analysis was performed by using R, version 2.15.1.
RESULTS
DASATINIB, CK59, AND CID755673 DECREASE NK CELL
DEGRANULATION AND CYTOKINE RELEASE IN PRIMARY HUMAN
PBMCs
To assess the influence of Dasatinib (inhibits SFKs), CK59 (inhibits
CaMKII), and CID755673 (inhibits PKD kinase family) on K562-
induced natural cytotoxicity of NK cells, the effector functions
(degranulation and cytokine release) were assessed by FACS-
based methods as previously described (Bryceson et al., 2010).
For these experiments PBMCs were isolated by density gradient
centrifugation from buffy coats of healthy human blood donors.
CD3−CD56+ NK cell populations were then defined by gating
PBMCs on lymphocytes, excluding doublets, as well as excluding
CD14+, CD19+, and dead cells (Figure A1 in Appendix). K562
cancer cells were used as target cells for the activation of NK cells
and to study natural cytotoxicity within the PBMC fraction. IL-12
and IL-18 support NK cell cytokine release triggered by target cell
recognition (Fauriat et al., 2010). By adding IL-12 and IL-18 the
responsiveness and viability of the cells was tested. Co-stimulation
with target cells, IL-12 and IL-18 significantly increased NK cell
cytokine production and to a minor extent NK cell degranulation
(Figure A2 in Appendix).
The specific inhibitors were added to PBMCs at indicated con-
centrations 15 min prior to activation with target cells. After 2 h
of co-incubation with target cells, degranulation was analyzed by
measuring CD107a surface expression. Cytokine release was deter-
mined by intracellular staining after treatment with GolgiPlug and
GolgiStop (both BD Biosciences). As the inhibitors were delivered
in DMSO, corresponding DMSO concentrations were added to
control samples and data are presented as activated cells relative
to those DMSO controls.
By measuring CD107a surface expression, it could be shown
that 150 nM Dasatinib reduced degranulation by 50% and nearly
led to complete abrogation at higher concentrations (Figure 1A).
Dasatinib applied at concentrations lower than 150 nM had no
significant effect on degranulation. Furthermore, Dasatinib led to
a significant inhibition of NK cell TNF-α and IFN-γ production
induced by target cell recognition, even at low concentrations. At
concentrations equal to or higher than 100 nM, release of TNF-
α was reduced to 15% while production of IFN-γ was almost
abrogated.
Under the same conditions, CK59 inhibited NK cell degran-
ulation also dose-dependently and more gradually in compari-
son to Dasatinib (Figure 1B). The kinase inhibitor CK59 also
reduced the number of cytokine producing cells without dis-
playing the same dose-dependence. Low inhibitor concentrations
(10–50µM) showed only a moderate reduction, whereas CK59
FIGURE 1 | Small molecule kinase inhibitors (Dasatinib, CK59, and
CID755673) decrease NK cell degranulation and cytokine release in
primary human PBMCs. PBMCs were treated with (A) Dasatinib,
directed against Src family kinases; (B) CK59, targeting CaMKII; and (C)
CID755673, inhibiting PKD family kinases and subsequently incubated
with K562 target cells at 37˚C for 2 (degranulation) and 6 (cytokine
release) hours, respectively. Cells were mixed with respective
fluorochrome-conjugated mAbs and the frequency of degranulating or
cytokine producing NK cells was determined via flow cytometry. Data
represent values relative to corresponding DMSO control. Comparison
of every inhibitor-treated group to its corresponding DMSO control
group was performed by Wilcoxon test (*P < 0.05,**P <0.01,
***P < 0.001). Values represent mean of the indicated number of
donors ±SD.
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applied at higher concentrations strongly reduced NK cell cytokine
production, which was nearly abrogated at 150µM. In general, the
effect of CK59 on TNF-α and IFN-γ production was comparable.
Thus, CK59 led to dose-dependent inhibition of NK cell degran-
ulation and had an even stronger effect on cytokine production at
higher concentrations.
CID755673 reduced NK cell degranulation as well as NK
cell cytokine release (Figure 1C). The number of degranu-
lating cells was significantly reduced at an inhibitor concen-
tration of 5µM. At higher concentrations NK cell degranula-
tion was reduced to 40%. Notably, it did not decrease further
when concentrations of CID755673 were raised to more than
50µM. However, increasing the concentration of the inhibitor
to 100µM led to a further reduction of cytokine production.
TNF-α production was also decreased dose-dependently and the
percentage of TNF-α-producing cells was reduced to approxi-
mately 25% at 100µM CID755673. The production of IFN-γ
was also decreased in a dose-dependent manner and almost
completely abrogated at a concentration of 100µM. In sum-
mary, CID755673 led to a significant inhibition of NK cell
effector functions, in which IFN-γ responses could be nearly
abolished.
Taken together, treatment of PBMC cultures with Dasatinib,
CK59, and CID755673 resulted in a significant inhibition of
NK cell effector functions, including degranulation and cytokine
release.
DONOR-SPECIFIC RESPONSES OF PURE NK CELLS TREATED WITH
DASATINIB, CK59, AND CID755673
To validate the effects of Dasatinib, CK59, and CID755673 on NK
cells and to reveal the potential contribution of other PBMCs, NK
cells were purified by MACS before inhibitor application and sub-
sequent activation with K562 target cells. Stimulation and FACS
analysis were performed as described before. Notably, donor varia-
tions became more obvious at the level of pure NK cells in contrast
to PBMCs for all three inhibitors.
Dasatinib showed an even more pronounced effect on degran-
ulation, which was completely abrogated at 100 nM (Figure 2A).
Release of TNF-α and IFN-γ also showed a strong reduction at
concentrations of 50 nM. Some donors exhibited an increased
release of TNF-α and IFN-γ after an initial reduction. After nearly
complete abrogation of TNF-α release, one donor showed an
increase in cells positive for TNF-α peaking at 200 nM and 30%
positive cells. Another donor showed an increased response at
10 nM. Release of IFN-γ even recovered to 60% positive cells for
two donors at concentrations of 100 and 150µM, respectively,
before it significantly decreased at higher concentrations.
Treatment with CK59 also generally decreased the number of
degranulating NK cells, with a reduction to 75% at 100µM and
almost complete abrogation at 150µM (Figure 2B). At the lowest
concentration of 10µM, however, NK cells of some donors showed
a slightly increased degranulation response. The effect on cytokine
release was more pronounced. The number of TNF-α positive cells
FIGURE 2 | Donor-specific responses of pure NK cells treated with
Dasatinib, CK59, and CID755673. Purified NK cells were treated with (A)
Dasatinib, directed against Src kinases; (B) CK59, targeting CaMKII; and (C)
CID755673, inhibiting PKD family kinases and subsequently incubated with
K562 target cells at 37˚C for 2 (degranulation) and 6 (cytokine release) hours,
respectively. Cells were mixed with respective fluorochrome-conjugated
mAbs and the frequency of degranulating or cytokine producing NK cells was
determined via flow cytometry. Data represents values relative to
corresponding DMSO control. Comparison of every inhibitor-treated group to
its corresponding DMSO control group was performed by Wilcoxon test
(*P <0.05,**P <0.01,***P <0.001). Values represent mean of the indicated
number of donors ±SD.
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was reduced to about 25% at 100µM, and diminished further at
150µM. Strikingly, the response of two donors was not inhibited
but significantly increased at low drug concentrations with a peak
of 250% at 20µM for one donor, which at higher concentrations
then dropped to 20% TNF-α positive cells in a dose-dependent
manner. The release of IFN-γ decreased dose-dependently in two
other donors. One of those, however, showed an increased num-
ber of positive cells at 10µM. More striking, two donors showed
an increased response of 140% at 20µM, with a decreased num-
ber of positive cells at higher concentrations. One donor even
showed a pronounced increase of cells releasing IFN-γ, peaking at
50µM with 340% positive cells compared to the corresponding
control.
The effect of CID755673 on pure NK cell degranulation was
moderate in comparison to PBMCs. CID755673 caused only lim-
ited but significant decrease in CD107a surface expression in all
donors except one, who showed a remarkable decrease at 200µM
(Figure 2C). Two donors also showed a moderate increase of
CD107a surface expression at concentrations of 50 and 100µM,
whereas the response of a further donor showed a similar response
signature at concentrations of 100 and 200µM. Higher concentra-
tions of CID755673 consistently led to a robust decrease of TNF-α
release in all donors. However, the number of TNF-α releasing cells
was dramatically increased at low concentrations of CID755673
for two donors, while another one showed a small increase at
10µM. Similar, all donors showed almost complete abrogation
of IFN-γ release at concentrations of 100µM or higher, whereas
donor variations became obvious at lower concentrations. Two
donors showed a pronounced increase of IFN-γ positive cells to
270 and 200%, respectively, after initial reduction at lower con-
centrations. Two other donors also showed a small recovery of the
IFN-γ response.
In summary, all inhibitors can decrease effector functions and
in a cumulative view, data obtained from pure NK resemble those
obtained from PBMCs. However, we observed a high number of
individual donor variations, resulting in recovering responses at
higher inhibitor concentrations after an initial decrease. Addition-
ally, some donors showed an increased response at low inhibitor
concentrations, with a subsequent decrease at higher concentra-
tions. All those variations were neither restricted to single donors,
nor to inhibitors or responses.
DISCUSSION
Generally NK cell activation can be subdivided into two mecha-
nisms: CD16-mediated ADCC and“natural”cytotoxicity. Whereas
CD16 engagement alone is sufficient to induce prominent NK
cell effector functions, natural cytotoxicity depends on the inter-
action between multiple activating receptors and the absence of
inhibitory receptors. In a previous study it was demonstrated that
engagement of CD16 as well as co-engagement of 2B4+DNAM-1
cause responses predominantly in the same set of protein kinases,
including CaMKII and PKD2, indicating their role in a core signal
network. However, the existence of a core signal network, act-
ing in both ADCC and natural cytotoxicity had to be clarified.
Here, K562 tumor cells were used to activate natural cytotoxic-
ity and to analyze the impact of the kinase inhibitors (Dasatinib,
CK59, and CID755673) on NK cell effector functions. K562 tumor
cells express ligands for receptors promoting natural cytotoxicity
(Nectin-2/PVR for DNAM-1; MICA/B/UBLP1 for NKG2D), but
do not express the 2B4 ligand CD48 or classical HLA-A, B, C,
and non-classical HLA-E (Hanson et al., 2007). When compar-
ing the signaling pathways induced by CD16-mediated ADCC-
and K562-mediated natural cytotoxicity, one has to take into
account the involved receptors. CD16 associates with TCRζ or/and
FcRγ, initiating the classical ITAM pathway of SFK-mediated tyro-
sine phosphorylation, whereupon Syk association leads to PI3K,
Vav1, and PLCγ-1 and 2 activation (Ting et al., 1995). This path-
way leads to cytoskeletal re-arrangements through the activation
of Rho, Rac, and Cdc42, and under MAPK involvement also
to degranulation. K562-mediated cytotoxicity includes receptor
signaling of DNAM-1/LFA-1,NKG2D,and NKp30. The three tyro-
sine residues of DNAM-1 can be phosphorylated by SFKs leading
to the recruitment of actin-binding proteins. DNAM-1 signaling
acts always co-activating, depends on its association with LFA-1
and therefore promotes cellular adhesion (Shibuya et al., 2003).
NKG2D signaling shares common features with the CD16 path-
way, but a DAP10 motif is associated with its receptor instead of
an ITAM (CD16). Notably, NKG2D signal transduction pathways
work independently of the trans-membrane adapter molecules
LAT and NTAL and do not require SYK or ZAP70 kinases, instead
of ADCC-mediated signaling (Billadeau et al., 2003) that mainly
induces degranulation. NKp30 associates also with TCRζ and/or
FcRγ chains, through the ITAM motif of the associated partner
chains. In conclusion, NK cell activation is very similar to sig-
naling events known from T or B cell activation, especially with
regard to the ITAM-based NK cell receptors such as CD16 and
NKp30.
Here, we investigated the effects of kinase inhibition by Dasa-
tinib, CK59, and CID755673 on K562-induced natural cyto-
toxicity of NK cells within PBMC populations and pure NK
cells isolated from human blood donors. They have been estab-
lished as valid tools for enzyme inhibition in particular at
the level of primary human immune cells (Krieg and Ullrich,
2012).
Dasatinib, formerly BMS-354825 or Sprycel®, is a multi-
targeted kinase inhibitor that is not restricted to SFKs but also
targets, e.g., the tyrosine kinase BCR-ABL1 (Lombardo et al.,
2004), and is generally used as drug in leukemia therapy. Due to the
structural homology of SFKs (Boggon and Eck, 2004), Dasatinib
has a relatively broad target spectrum. Therefore, Dasatinib serves
as a useful tool for proof-of-concept experiments, as SFKs play a
major role in NK cell activation (Vivier et al., 2004; Lanier, 2008).
The potency of Dasatinib was underlined by previous experiments,
which showed its efficiency in inhibiting the effector functions of
NK cells in vitro (Blake et al., 2008; Fraser et al., 2009; Salih et al.,
2010). Consequently, the results of our study were completely in
accordance with the data of Salih and colleagues. Additionally,
our results showed remarkably reduced degranulation events and
TNF-α secretion in PBMC fractions and pure NK cells. However,
it was demonstrated recently that a 24-h-pretreatment with Dasa-
tinib, followed by wash off led to dose-dependent enhancement
of NK cell cytokine production, CD107a expression, and cytotox-
icity against selected lymphoma and leukemia cell lines (Hassold
et al., 2012). This ability of NK cells to recover effector functions
www.frontiersin.org March 2013 | Volume 4 | Article 66 | 5
Scheiter et al. Inhibition of NK cell effector functions
after longer Dasatinib pretreatment might be explained by phys-
iological adaptation of the cells to drug exposure. In contrast to
Dasatinib, CK59, and CID755673 are considered as highly specific
kinase inhibitors.
CK59 is an analog of the kinase inhibitor olomoucine, which
was demonstrated to specifically inhibit CaMKII isoforms. Indeed,
CaMKII-γ and CaMKII-δ were found to be the kinases with
the highest affinity to immobilized CK59 (Konstantopoulos
et al., 2007). Incubation of immune-precipitated CaMKII in vitro
showed that 10µM CK59 reduce CaMKII activity by 55%. It
has already been shown that inhibition of CaMKII prevents NK
cell-mediated killing of autologous dendritic cells (DC) (Poggi
et al., 2002). The secretion of IFN-γ by NK cells upon contact
with DCs, which activates the DCs, is also inhibited. Interest-
ingly, our results are at variance with the results of Poggi and
colleagues. Poggi and colleagues reported that the inhibition of
CaMKII did not significantly reduce K562 target cell killing by
NK cells, whereas this was demonstrated in this study. To explain
these differences, it has to be considered that we studied degranu-
lation and cytokine release, whereas Poggi and colleagues analyzed
the specific lysis of target cells, measured by Chromium51 release.
Furthermore, we analyzed degranulation after 2 h in CD3−CD56+
NK cells and Poggi and colleagues after 4 h in CD3−CD16+ NK
cells, also using completely different CaMKII inhibitors (KN62
and KN93). Therefore, CaMKII might only be involved in cellu-
lar processes coordinating degranulation, but not the killing of
target cells.
According to the PubChem database CID755673 inhibits exclu-
sively the PKD kinase family comprising PKD1, PKD2, and PKD3
and does not exhibit any biological effect in 200 other assays
(Sharlow et al., 2008). No inhibition is documented for the
PKD upstream protein kinase C (PKC) or CaMKII that was also
investigated here. This further underlines its high specificity, as
these kinases are closely related to PKD indicated by high overall
sequence homology (PKC; Sturany et al., 2001) and high homology
of the catalytic domain (CAMKs; Sharlow et al., 2008), respectively.
PKD2 is considered as a signaling component in NK cells but func-
tional data are currently missing. PKD isoforms are not involved in
integrin-mediated lymphocyte adhesion and homing to lymphoid
tissues (Matthews et al., 2012). In the present study, application of
CID755673 resulted in a significant alteration of degranulation
and cytokine release. These observations suggest that PKD family
kinases are participating in the signal network coordinating NK
cell effector functions.
Dose-dependent alterations of effector functions were also
found for all three inhibitors with pure NK cells maintained by
IL-2. However, in comparison to studies performed in PBMCs
the caused alterations were distinct in two aspects: (i) individ-
ual donors exhibited remarkably different response profiles and
(ii) all inhibitors have the potential to even increase NK effector
functions. Both effects indicate that the targeted kinases can also
contribute to inhibitory pathways. Protein kinases are often rec-
ognized as “overconnected” and, e.g., Fyn is part of more than 50
canonical pathways. Their pathway-specific function is assumed
to be realized by distinct post-translational modifications coor-
dinating both kinase activity and substrate binding. Previously,
it was shown that the PKD2 activation status correlates directly
with in vivo phosphorylation of S876 within transfected HEK293
cells (Sturany et al., 2001) and CaMKII activation depends on
phosphorylation at Thr286 (Larsson and Broman, 2005). König
and colleagues described the regulation of further modifications
so far not functionally characterized. NK cell receptor engage-
ments induce phosphorylation of PKD2 at serine 214 and of
CaMKIIat serine 330 (König et al., 2012). Several other phos-
phorylations sites are known but a detailed mechanistic model
for both kinases is still missing. However, the expression of kinase
isoforms has to be taken into account to better understand donor
variations and apparently contradicting results in this research
field: it is known that different protein kinase C isoforms (PKCδ,
ε, θ, and η) are acting as upstream signal components of PKD
family kinase isoforms (PKD1, PKD2, and PKD3) (Yuan et al.,
2002; Rozengurt et al., 2005; Döppler and Storz, 2007) making
this signaling network even more complex. Presently it is known
that PKCδ phosphorylates PKD1 and PKD2, whereas PKCε and
PKCη exclusively activate PKD1 (Waldron et al., 1999; Brändlin
et al., 2002; Döppler and Storz, 2007). Data concerning the spe-
cific isoforms interacting with PKCθ and PKD3 and leading to
their phosphorylation are missing. Notably, PKCθ is essential for
ITAM-mediated release of IFN-γ and TNF-α, but not for NK cell-
mediated cytotoxicity or cytokine release induced by IL-12 and
IL-18 (Tassi et al., 2008). In contrast, Page et al. (2008) determined
a diminished IL-12-induced IFN-γ response of NK cells in PKCθ
deletion mutant mice (PKCθ−/−), but did not detect a reduction
of cytotoxic capacity against YAC-1 cells. Furthermore, PKCθ−/−
mice showed reduced, but not abrogated degranulation against
MHC-I negative RMA-S tumor cells (Aguiló et al., 2009). Thus, it
was shown that, chemical inhibition of the PKC downstream sig-
naling component PKD leads to a more pronounced inhibition of
NK cell effector functions than the isoform-specific knock-out of
upstream kinase PKCθ. We hypothesize that the signaling pathway
leading to NK cell activation depends not solely on PKCθ, but also
involves other isoforms of PKC that phosphorylate one or more
PKD isoforms (Figure 3).
In conclusion, chemical inhibition of either CaMKII or PKD
family kinases limits NK cell effector functions. Results from nat-
ural cytotoxicity further substantiated the role of these kinases
in NK cell signaling. However, the results with pure NK cells
also indicate the importance to further investigate the molecular
basis of donor variations, which may be caused either by differ-
ential pre-activation of kinases at the level of post-translational
FIGURE 3 | Schematic representation of known and potential
interactions between PKC and PKD family kinase isoforms. Continuous
lines indicate known interactions between specific PKC and PKD family
kinase isoforms leading to activation through phosphorylation of the latter.
Potential interactions of specific PKDs with PKCθ isoforms, to this date not
experimentally validated, are shown as dashed lines.
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modifications or simply by differential expression of kinase
isoforms.
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APPENDIX
FIGURE A1 | Gating strategy to study effector functions of human
CD3−CD56+ NK cells. NK cells were co-incubated with K562 target cells for
6 h for assessment of cytokine production and 2 h for investigating
degranulation at 37˚C. After stimulation, cells were surface stained with
fluorochrome-conjugated mAbs directed against CD3, CD14, CD19, CD56,
and CD107a, as well as with DCM. The depicted gates were used to exclude
(A) non-lymphocytes, (B) doublets, (C) CD14+/CD19+, and dead cells as well
as (D) CD3+CD56− cells from the analysis.
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FIGURE A2 | Activation of NK cell effector functions by co-incubation
with K562 target cells, IL-12 and IL-18. (A) PBMCs were incubated with or
without K562 target cells, as well as in combination with IL-12 and IL-18 for 6 h
at 37˚C, fixed, permeabilized, and stained with respective
fluorochrome-conjugated mAbs. Dot plots show CD107a expression and
cytokine production of NK cells without target cells or co-cultured with K562
cells, IL-12, and IL-18. Non-activated cells showed no significant responses
(upper panel), incubation with target cells triggered degranulation and
cytokine production (middle panel) and supplementation of IL-12 and IL-18 lead
to higher cytokine production (lower panel). Results from one representative
donor are shown. (B) Increase of NK cell degranulation and cytokine release
by K562 target cells and supplementation of IL-12 and IL-18 to validate the
viability and responsiveness of the cells. Values represent mean of five
individual donors ±SD.
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